Akebia Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

Akebia Therapeutics, Inc. stands as a leading company in Healthcare. Generating $236.20 million in annual revenue (growing 23.9% year-over-year) and carrying a market capitalization of $315.79 million, the company has cemented its position as a foundational player in the global Drug Manufacturers - Specialty & Generic landscape. Under the leadership of its leadership team, Akebia Therapeutics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Akebia Therapeutics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Akebia Therapeutics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Akebia Therapeutics, Inc.'s position in the Drug Manufacturers - Specialty & Generic market today.

What You Will Learn

1. How Akebia Therapeutics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Akebia Therapeutics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Akebia Therapeutics, Inc.'s main competitors are and how the company compares on key financial metrics
4. Akebia Therapeutics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Akebia Therapeutics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $236.20 million annual revenue (TTM), +23.9% YoY
• Market Cap: $315.79 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 82.9%, operating margin -10.5%, net margin -2.3%
• Free Cash Flow: $68.61 million
• Return on Equity: N/A — reflects current investment phase
• Employees: 194 worldwide

Who Owns Akebia Therapeutics, Inc.?

Akebia Therapeutics, Inc. is publicly traded on the NASDAQ under the ticker symbol AKBA. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Akebia Therapeutics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Akebia Therapeutics, Inc. has approximately 265 million shares outstanding, with float shares of 0 million — the freely tradeable portion. The stock trades at $1.19 per share as of early 2026.

Akebia Therapeutics, Inc.'s Mission Statement

Akebia Therapeutics, Inc.'s strategic mission is aligned with its core business activities in the Drug Manufacturers - Specialty & Generic sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Akebia Therapeutics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Akebia Therapeutics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Akebia Therapeutics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Akebia Therapeutics, Inc. Make Money?

As of 2026, Akebia Therapeutics, Inc. generates $236.20 million in annual revenue (growing 23.9% year-over-year), with a 82.9% gross margin and -10.5% operating margin. Market capitalization stands at $315.79 million. Here is how the company generates its revenue:

As of 2026, Akebia Therapeutics, Inc. generates $236.20 million in annual revenue (growing 23.9% year-over-year), with a 82.9% gross margin and -10.5% operating margin. Market capitalization stands at $315.79 million. Here is how the company generates its revenue:

Revenue Streams

Akebia Therapeutics Inc generates its revenue through several key streams.

Product Sales

The primary source of revenue for Akebia Therapeutics Inc is the sales of its pharmaceutical products. The company develops and markets innovative therapeutics for the treatment of kidney diseases and other related conditions. Their flagship product, Auryxia, is an oral medication approved for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Akebia Therapeutics Inc sells Auryxia to healthcare providers, hospitals, and pharmacies, generating substantial revenue from these sales.

Licensing and Collaboration Agreements

In addition to product sales, Akebia Therapeutics Inc also generates revenue through licensing and collaboration agreements. The company collaborates with various pharmaceutical companies, academic institutions, and research organizations to develop and commercialize its products. Through these collaborations, Akebia Therapeutics Inc receives upfront payments, milestone payments, and royalties based on product sales. These agreements provide the company with a steady stream of revenue and also help in expanding its product portfolio and research capabilities.

Grants and Funding

Akebia Therapeutics Inc also secures grants and funding from government agencies, non-profit organizations, and private investors. These grants and funding are typically awarded to support the company's research and development efforts, clinical trials, and other scientific initiatives. By securing external funding, Akebia Therapeutics Inc reduces its financial burden and can invest more resources into advancing its drug development programs.

Conclusion

Akebia Therapeutics Inc employs a diversified approach to generate revenue. While product sales remain the primary source of income, the company leverages licensing and collaboration agreements to expand its reach and revenue potential. Additionally, securing grants and funding allows Akebia Therapeutics Inc to maintain a robust research and development pipeline. Through these revenue streams, Akebia Therapeutics Inc not only sustains its operations but also continues to innovate and deve

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Akebia Therapeutics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Akebia Therapeutics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Akebia Therapeutics, Inc. creates, delivers, and captures value.

Key Partners: Akebia Therapeutics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Drug Manufacturers - Specialty & Generic sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Akebia Therapeutics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Akebia Therapeutics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (194 employees), proprietary technology, and financial resources ($184.84M in cash).

Value Propositions: Akebia Therapeutics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Drug Manufacturers - Specialty & Generic market.

Customer Relationships: Akebia Therapeutics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Akebia Therapeutics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Akebia Therapeutics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Akebia Therapeutics, Inc.'s major costs include cost of goods sold (17.1% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 110.5% of revenue.

Revenue Streams: Akebia Therapeutics, Inc. generates revenue through its core product and service offerings.

Akebia Therapeutics, Inc. Competitors

Akebia Therapeutics, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector.

Akebia Therapeutics, Inc. SWOT Analysis

A SWOT analysis examines Akebia Therapeutics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Akebia Therapeutics, Inc.'s gross margin of 82.9% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -10.5% demonstrates disciplined cost management even at scale.
• Revenue Growth: Revenue grew 23.9% year-over-year to $236.20M, indicating strong demand for Akebia Therapeutics, Inc.'s products and services and outperformance relative to many industry peers.

Weaknesses

• High Financial Leverage: With a debt-to-equity ratio of 609.6, Akebia Therapeutics, Inc. carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnerability to rising interest rates.

Opportunities

• Total Addressable Market: Akebia Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Akebia Therapeutics, Inc.'s products and services.
• Strategic Acquisitions: With $184.84M in cash and strong free cash flow generation, Akebia Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Akebia Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Akebia Therapeutics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Akebia Therapeutics, Inc. enters 2026 as a leading company in Healthcare, backed by $236.20 million in annual revenue and a -2.3% net profit margin. The company's 82.9% gross margins and $68.61 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Akebia Therapeutics, Inc.'s core markets.

For investors and analysts, Akebia Therapeutics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Akebia Therapeutics, SEC EDGAR – Akebia Therapeutics Filings, and Akebia Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does Akebia Therapeutics, Inc. do?

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chro

2. How much revenue does Akebia Therapeutics, Inc. make?

Akebia Therapeutics, Inc. generated $236.20 million in annual revenue (TTM), with 23.9% year-over-year growth.

3. What is Akebia Therapeutics, Inc.'s market cap?

Akebia Therapeutics, Inc.'s market capitalization is approximately $315.79 million as of early 2026.

4. Is Akebia Therapeutics, Inc. profitable?

Akebia Therapeutics, Inc. has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

5. Who are Akebia Therapeutics, Inc.'s competitors?

Akebia Therapeutics, Inc. competes in the Drug Manufacturers - Specialty & Generic sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does Akebia Therapeutics, Inc. pay dividends?

Akebia Therapeutics, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is Akebia Therapeutics, Inc.'s stock ticker?

Akebia Therapeutics, Inc. trades on the NASDAQ under the ticker symbol AKBA.

8. What is Akebia Therapeutics, Inc.'s P/E ratio?

Valuation multiples for Akebia Therapeutics, Inc. can be found on major financial platforms such as Yahoo Finance, Bloomberg Terminal, or the company's latest annual report filing.

9. How many employees does Akebia Therapeutics, Inc. have?

Akebia Therapeutics, Inc. employs approximately 194 people worldwide as of the most recent disclosure.

10. What is Akebia Therapeutics, Inc.'s competitive advantage?

Akebia Therapeutics, Inc.'s competitive advantages include its established brand, scale in Drug Manufacturers - Specialty & Generic, and track record of execution in the Healthcare sector.